Skip to main content

Table 1 Patient characteristics

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Characteristics

Cases (n = 19)

Patient age, median (range), years

33 (3–57)

Sex

 Male

13

 Female

6

Diagnosis

 AML

3

 ALL

7

 MDS

7

 PID

2

Pre-HSCT EBV status, donor/recipient

 Positive/positive

19

MNC, median (range), × 108/kg

5.17 (2.53–9.59)

CD34+ cell absolute count, median(range), ×106/kg

6.37 (1.61–11.13)

CD3+ cell absolute count, median(range), ×108/kg

2.76 (0.82–7.83)

Engraftment

 White cells, median (range), days

12 (10–18)

 Platelets, median (range), days

13 (9–18)

Acute graft-versus-host disease, n

 No

7

 I–II degree

10

 III–IV degree

2

EBV infection after HSCT within 100 days

 No

9

 EBV-DNAemia

5

 EBV disease

5

CSA stop

 No

4

 Yes

15

CSA stopping time, median (range), days

32.5 (4–88)